Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neurotrauma ; 27(5): 901-10, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20121416

RESUMEN

We reported that adenosine A(1) receptor (A(1)AR) knockout (KO) mice develop lethal status epilepticus after experimental traumatic brain injury (TBI), which is not seen in wild-type (WT) mice. Studies in epilepsy, multiple sclerosis, and neuro-oncology suggest enhanced neuro-inflammation and/or neuronal death in A(1)AR KO. We hypothesized that A(1)AR deficiency exacerbates the microglial response and neuronal damage after TBI. A(1)AR KO and WT littermates were subjected to mild controlled cortical impact (3 m/sec; 0.5 mm depth) to left parietal cortex, an injury level below the acute seizure threshold in the KO. At 24 h or 7 days, mice were sacrificed and serial sections prepared. Iba-1 immunostaining was used to quantify microglia at 7 days. To assess neuronal injury, sections were stained with Fluoro-Jade C (FJC) at 24 h to evaluate neuronal death in the hippocampus and cresyl violet staining at 7 days to analyze cortical lesion volumes. We also studied the effects of adenosine receptor agonists and antagonists on (3)H-thymidine uptake (proliferation index) by BV-2 cells (immortalized mouse microglial). There was no neuronal death in CA1 or CA3 quantified by FJC. A(1)AR KO mice exhibited enhanced microglial response; specifically, Iba-1 + microglia were increased 20-50% more in A(1)AR KO versus WT in ipsilateral cortex, CA3, and thalamus, and contralateral cortex, CA1, and thalamus (p < 0.05). However, contusion and cortical volumes did not differ between KO and WT. Pharmacological studies in cultured BV-2 cells indicated that A(1)AR activation inhibits microglial proliferation. A(1)AR activation is an endogenous inhibitor of the microglial response to TBI, likely via inhibition of proliferation, and this may represent a therapeutic avenue to modulate microglia after TBI.


Asunto(s)
Lesiones Encefálicas/metabolismo , Gliosis/metabolismo , Inhibidores de Crecimiento/fisiología , Microglía/metabolismo , Receptor de Adenosina A1/metabolismo , Adenosina/metabolismo , Animales , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/patología , Línea Celular Transformada , Corteza Cerebral/lesiones , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Femenino , Gliosis/tratamiento farmacológico , Gliosis/patología , Inhibidores de Crecimiento/deficiencia , Inhibidores de Crecimiento/genética , Hipocampo/metabolismo , Hipocampo/patología , Masculino , Ratones , Ratones Noqueados , Microglía/efectos de los fármacos , Microglía/patología , Degeneración Nerviosa/etiología , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/patología , Receptor de Adenosina A1/deficiencia , Receptor de Adenosina A1/genética , Tálamo/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA